Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV05SW)

Drug Name

AS-1670542 Drug Info

Synonyms

AVATROMBOPAG; 570406-98-3; AKR-501; UNII-3H8GSZ4SQL; 3H8GSZ4SQL; AKR 501; Avatrombopag [USAN:INN]; Doptelet; AS 1670542; Avatrombopag (USAN/INN); GTPL9953; DTXSID30205667; ZINC72190218; AKOS027323962; CS-3397; HY-13463; FT-0728753; D10306; AS1670542

Indication

Disease Entry	ICD 11	Status	REF
Thrombocytopenia	3B64	Approved	[1]
Idiopathic thrombocytopenic purpura	3B64.10	Phase 3	[2]

Cross-matching ID

PubChem CID: 9852519
CAS Number: CAS 570406-98-3
TTD Drug ID: DMV05SW
ACDINA Drug ID: D00852

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Thrombopoietin receptor (MPL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[4]
Eltrombopag	DMOGFIX	Thrombocytopenia	3B64	Approved	[5]
Lusutrombopag	DMH6IKO	Thrombocytopenia	3B64	Approved	[1]
LGD-4665	DM9T8A2	Immune thrombocytopenic purpura	3B64.13	Phase 2	[5]
BVI-007	DM43GPX	Myocardial infarction	BA41-BA43	Phase 1	[3]
NIP-004	DM0PYEQ	Thrombocytopenia	3B64	Phase 1	[6]
RhTPO	DMCV0BZ	Idiopathic thrombocytopenic purpura	3B64.10	Discontinued in Phase 3	[5]
Totrombopag	DM6SUDC	Thrombocytopenia	3B64	Discontinued in Phase 1	[7]
Promegapoietin	DMS4FG0	Bone marrow transplantation	QB63.6	Terminated	[8]
SB-559457	DM0OLYF	Acute myeloid leukaemia	2A60	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Thrombopoietin receptor (MPL)	TTIHYA4	TPOR_HUMAN	Agonist	[3]

------------------------------------------------------------------------------------

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	ClinicalTrials.gov (NCT01433978) A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura). U.S. National Institutes of Health.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
4	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
5	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
6	A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood. 2006 Jun 1;107(11):4300-7.
7	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.